The study to evaluate the efficacy and safety of using Platelet-rich plasma for treating melasma in Thailand
Phase 4
Completed
- Conditions
- Healthy human volunteersPRP, Platelet-rich plasma, Melasma
- Registration Number
- TCTR20220516004
- Lead Sponsor
- Dermatologic Surgery, Dermatology department, Siriraj hospital, Thailand
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
1. Epidermal or mixed types melasma2. Thais 3. Healthy
Exclusion Criteria
1. pregnant or lactating woman 2. Having severe acnes 3. Having the skin disease around the treated area 4. Using an energy-based device or other interventions around treated area 6 months prior
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Melasma improvement Every treatment visits, 14 days, 1, 2, 3, and 6 months after the intervention Level of improvement measure from Antera3d,Subject self assessment score Every treatment visits, 14 days, 1, 2, 3, and 6 months after the intervention percentage of Subject self assessment score,Physicians assessment score Every treatment visits, 14 days, 1, 2, 3, and 6 months after the intervention percentage of Physicians assessment score
- Secondary Outcome Measures
Name Time Method Pain score immediate after the intervention Visual analogue scale (0-10),Adverse reaction Every treatment visits, 14 days, 1, 2, 3, and 6 months after the intervention Descriptive report